Bioatla

Bioatla Equity

The The Equity of Bioatla (BCAB) as of Nov 18, 2026 is -36.19 M USD. In the previous year, The Equity was 14.27 M USD — a change of -353.69% (lower).

Equity

-36.19 MUSD

YoY

-353.69%

Last updated:

In 2025, Bioatla's equity was -36.19 M USD, a -353.69% increase from the 14.27 M USD equity in the previous year.

The Bioatla Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-28.47 M USD
Jan 1, 2019
-55.96 M USD
Jan 1, 2020
209.97 M USD
Jan 1, 2021
210.82 M USD
Jan 1, 2022
180.34 M USD
Jan 1, 2023
70.67 M USD
Jan 1, 2024
14.27 M USD
Jan 1, 2025
-36.19 M USD
The Bioatla Equity history
YEAREquityYoY
-36.19 MUSD-353.69%
14.27 MUSD-79.82%
70.67 MUSD-60.81%
180.34 MUSD-14.46%
210.82 MUSD+0.40%
209.97 MUSD-475.19%
-55.96 MUSD+96.61%
-28.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bioatla's Equity

Bioatla's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bioatla's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bioatla's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bioatla's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bioatla’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bioatla stock

The Equity of Bioatla is -36.19 M USD in 2025.

The Equity of Bioatla changed from 14.27 M USD to -36.19 M USD, representing a -353.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bioatla since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bioatla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioatla

All Key Metrics — Bioatla